Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Emerging biomarkers in MS: the value of serum NfL

Augusto Miravalle • 8 Apr 2022
AAN 2022
Multiple Sclerosis and Related Disorders

Augusto Miravalle, MD, FAAN, University of Colorado School of Medicine, Aurora, CO, discusses emerging biomarkers of disease response and prognosis in multiple sclerosis (MS) and how these biomarkers may aid treatment decision-making. Dr Miravalle first emphasizes the value of using serum neurofilament light chain protein (NfL) to better understand inflammatory activity and predict patient response to therapies and further highlights the importance of combining various biomarkers and using more advanced MRI techniques. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

More from Augusto Miravalle

The role of BTK in MS pathophysiology and developments in BTK-targeting therapies
2:42
The role of BTK in MS pathophysiology and developments in BTK-targeting therapies
Augusto Miravalle • 21 Apr 2026
The contemporary view of MS as a single disease with distinct biologies
1:27
The contemporary view of MS as a single disease with distinct biologies
Augusto Miravalle • 21 Apr 2026
Chronic inflammation in MS
2:12
Chronic inflammation in MS
Augusto Miravalle • 5 May 2023
Understanding of the early disease processes in MS
2:19
Understanding of the early disease processes in MS
Augusto Miravalle • 5 May 2023

Related Videos

What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
6:48
What are the key changes introduced in the 2024 revision of the McDonald diagnostic criteria for MS?
Mar Tintoré • 3 Jul 2026
Ovarian aging and long-term prognosis in women with multiple sclerosis
3:07
Ovarian aging and long-term prognosis in women with multiple sclerosis
Mar Tintoré • 3 Jul 2026
The emerging role of AI in the diagnosis and management of multiple sclerosis
1:55
The emerging role of AI in the diagnosis and management of multiple sclerosis
Celia Oreja-Guevara • 29 Jun 2026
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
3:15
Can selected patients with multiple sclerosis safely discontinue ocrelizumab?
Franz Felix Konen • 28 Jul 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals